Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The epirubicin/docetaxel combination is one of the most active and best tolerated
taxane/anthracycline combinations. In this phase II trial, we will further evaluate the
feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when
administered as first-line treatment for metastatic breast cancer.